Virani, Salim S.

Combating non-communicable diseases: potentials and challenges for community health workers in a digital age, a narrative review of the literature

Mishra, S. R., Lygidakis, C., Neupane, D., Gyawali, B., Uwizihiwe, J. P., Virani, S. S., Kallestrup, P., & Miranda, J. J. (2019) · Health Policy and Planning

Mobile Health and mHealth ApplicationsICT in Developing Communities

Cited by 71

A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies

Brautbar, A., Pompeii, L. A., Dehghan, A., Ngwa, J. S., Nambi, V., Virani, S. S., Rivadeneira, F., Uitterlinden, A. G., Hofman, A., Witteman, J. C. M., et al. (2012) · Atherosclerosis

Genetic Associations and EpidemiologyNutrition, Genetics, and Disease

Cited by 71

Triglycerides and ASCVD risk reduction: recent insights and future directions

Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 57

Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry–Practice Innovation and Clinical Excellence Registry

Virani, S. S., Kennedy, K. F., Akeroyd, J. M., Morris, P. B., Bittner, V. A., Masoudi, F. A., Stone, N. J., Petersen, L. A., & Ballantyne, C. M. (2018) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthCoronary Interventions and Diagnostics

Cited by 53

Favorable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs and Resource Utilization: The 2012 Medical Expenditure Panel Survey

Valero-Elizondo, J., Salami, J. A., Ogunmoroti, O., Osondu, C. U., Aneni, E. C., Malik, R., Spatz, E. S., Rana, J. S., Virani, S. S., Blankstein, R., et al. (2016) · Circulation: Cardiovascular Quality and Outcomes

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 51

Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States

Satish, P., Sadaf, M. I., Valero-Elizondo, J., Grandhi, G. R., Yahya, T., Zawahir, H., Javed, Z., Mszar, R., Hanif, B., Kalra, A., et al. (2021) · American Journal of Preventive Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk Factors

Cited by 48

Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System

Jia, X., Al Rifai, M., Ramsey, D. J., Ahmed, S. T., Akeroyd, J. M., Nambi, V., Ballantyne, C. M., Petersen, L. A., Stone, N. J., & Virani, S. S. (2019) · The American Journal of Medicine

Medication Adherence and ComplianceLipoproteins and Cardiovascular Health

Cited by 41

The Fibrates Story — A Tepid End to a PROMINENT Drug

Virani, S. S. (2022) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 40

Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials

Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 39

Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification

Rana, J. S., Virani, S. S., Moffet, H. H., Liu, J. Y., Coghlan, L. A., Vasadia, J., Ballantyne, C. M., & Karter, A. J. (2022) · The American Journal of Medicine

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 35

Association between omega-3 fatty acid treatment and atrial fibrillation in cardiovascular outcome trials: a systematic review and meta-analysis

Jia, X., Gao, F., Pickett, J. K., Al Rifai, M., Birnbaum, Y., Nambi, V., Virani, S. S., & Ballantyne, C. M. (2021) · Cardiovascular Drugs and Therapy

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 27

New approaches to triglyceride reduction: is there any hope left?

Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 26

High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better

Grundy, S. M., Stone, N. J., Blumenthal, R. S., Braun, L. T., Heidenreich, P. A., Lloyd-Jones, D., Orringer, C. E., Saseen, J. J., Smith, S. C., Sperling, L. S., et al. (2021) · Mayo Clinic Proceedings

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 20

Nondietary cardiovascular health metrics with patient experience and loss of productivity among US adults without cardiovascular disease: the medical expenditure panel survey 2006 to 2015

Tibuakuu, M., Okunrintemi, V., Savji, N., Stone, N. J., Virani, S. S., Blankstein, R., Thamman, R., Blumenthal, R. S., & Michos, E. D. (2020) · Journal of the American Heart Association

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 20

The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials

Sayed, A., Shazly, O., Slipczuk, L., Krittanawong, C., Baloch, F., & Virani, S. S. (2024) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 19

Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center

Tran, C., Vo, V., Taylor, P., Koehn, D. A., Virani, S. S., & Dixon, D. L. (2022) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 17

Association Between Poverty and Appropriate Statin Prescription for the Treatment of Hyperlipidemia in the United States: An Analysis From the ACC NCDR PINNACLE Registry

Tanguturi, V. K., Kennedy, K. F., Virani, S. S., Maddox, T. M., Armstrong, K., & Wasfy, J. H. (2020) · Cardiovascular Revascularization Medicine

Lipoproteins and Cardiovascular HealthHealth disparities and outcomes

Cited by 14

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date

Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 14

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future

Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 12

Favorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS)

Feldman, D. I., Valero-Elizondo, J., Salami, J. A., Rana, J. S., Ogunmoroti, O., Osondu, C. U., Spatz, E. S., Virani, S. S., Blankstein, R., Blaha, M. J., et al. (2017) · Atherosclerosis

Diabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Cited by 11

Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH

Virani, S. S., Nambi, V., & Ballantyne, C. M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 10

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions

Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S. (2023) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9

Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?

Abdul Jabbar, A. B., Inam, M., Butt, N., Khan, S. S., Sheikh, S., Khoja, A., Perry, B., Gomez, G. Z., Slipczuk, L., & Virani, S. S. (2025) · Current Atherosclerosis Reports

Health Promotion and Cardiovascular PreventionLipoproteins and Cardiovascular Health

Cited by 7

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies

Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 4